Two-phase matrix for sustained release drug delivery device

Patent 5989586 Issued on November 23, 1999. Estimated Expiration Date:

November 23, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

Silicone elastomer transdermal matrix system
Patent #: 4814173
Issued on: 03/21/1989
Inventor: Song , et al.

Method for treating schizophrenia
Patent #: 4882352
Issued on: 11/21/1989
Inventor: Horn

Method and compositions for treatment of parkinsonism syndrome in mammals
Patent #: 4885308
Issued on: 12/05/1989
Inventor: Horn

Transdermal drug-delivery composition
Patent #: 4906463
Issued on: 03/06/1990
Inventor: Cleary, et al.

Active agent delivery device
Patent #: 4959208
Issued on: 09/25/1990
Inventor: Chakrabarti, et al.

Method and compositions for treatment of parkinsonism syndrome in mammels
Patent #: 4996226
Issued on: 02/26/1991
Inventor: Horn

System and method for transdermal drug delivery
Patent #: 5028435
Issued on: 07/02/1991
Inventor: Katz, et al.

Process of producing an active agent delivery device
Patent #: 5071645
Issued on: 12/10/1991
Inventor: Johnson, et al.

6-amino-1,4-hexahydro-1H-diazepine derivatives
Patent #: 5166341
Issued on: 11/24/1992
Inventor: Kon, et al.

External preparation comprising calcium silicate
Patent #: 5204119
Issued on: 04/20/1993
Inventor: Shiobara, et al.

More ...

Inventors

Application

No. 056076 filed on 04/30/1993

US Classes:

424/449, Transdermal or percutaneous424/447, Bandages with incorporated medicaments424/448, Pressure sensitive adhesive means424/484Matrices

Examiners

Primary: Harrison, Robert H.

Attorney, Agent or Firm

Horne; Angela P., McClung; Barbara G.

International Classes

A61F 013/00
A61F 013/02
A61F 009/70

Abstract

A two-phase hydrophilic drug-containing matrix for use in transdermal drug delivery patches in which one phase is a continuous hydrophobic polymer phase which optionally includes a hydrophobic solvent that acts as a skin permeation enhancer and the other phase is a dispersed particulate hydrated inorganic silicate in whose absorbed aqueous phase the drug is dissolved.